サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：血液がん治療薬の世界市場- 2023-2030
市場調査レポート
商品コード
1290434

血液がん治療薬の世界市場- 2023-2030

Global Blood Cancer Drugs Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血液がん治療薬の世界市場- 2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

血液がん治療薬の世界市場規模は2022年に630億米ドルに達し、2030年には最大1,135億米ドルに達することで有利な成長を示すと予測されます。血液がん治療薬の世界市場は、2023年から2030年の予測期間中に7.8%のCAGRを示すと予測されています。主要な市場動向は、免疫療法の急速な進歩です。

例えば、2023年4月、よりスマートで早期のがん治療を可能にする次世代プレシジョンオンコロジー企業であるStrata Oncology, Inc.は、進行がん患者向けの世界初の分子プロファイリング検査「Strata Select」の発売を発表しました。

この新しい診断テストは、抗PD-1/PD-L1チェックポイント阻害剤免疫療法の効果に関する新しい多変量予測バイオマーカーアルゴリズムである「Immunotherapy Response Score」を備えています。血液がん治療薬は、化学療法、分子標的治療薬、免疫療法、支持療法など、血液や骨髄中のがん細胞を特異的に標的とし、その増殖を抑制することを目的とした多様な治療介入を包含しています。

これらの薬剤は、異常な細胞プロセスを破壊し、がん細胞の増殖を抑制し、アポトーシスを誘導し、正常な血液細胞の生産と機能を回復させることを目的としています。

血液がん治療薬市場は、血液がんの有病率の増加、がん研究の進歩、標的治療薬、免疫治療薬、個別化医療の開発などの要因によって牽引されています。

例えば、2023年5月、Amneal Pharmaceuticals, Inc.は、Neulastaを参照するバイオシミラーであるFYLNETRAを充填済み単回投与シリンジで商業的に発売することを発表しました。FYLNETRAは、化学療法を受ける患者が一般的に経験する好中球減少症の治療に使用されます。

市場力学

血液がんの増加

血液がんの有病率の増加は、予測期間中の市場シェアを押し上げる主要因です。血液がん、特に白血病、リンパ腫、多発性骨髄腫などの特定のタイプのがんは、高齢者に多く診断されます。世界人口の高齢化が進むにつれ、血液がんの発生率は全体的に増加しています。

特定の環境要因への曝露や不健康な生活習慣の選択は、血液がんの発症リスクを高める可能性があります。環境要因には、放射線、特定の化学物質、農薬、産業汚染物質への曝露が含まれます。また、喫煙、過度の飲酒、座りっぱなしの生活などの不健康な行動も、血液がんの発症につながる可能性があります。

高額な治療費と副作用

血液がん治療薬は、研究開発に多大な労力を費やし、製造や試験工程が複雑であるため、高額な費用がかかることが多いです。これらの薬剤のコストは、患者、ヘルスケアシステム、支払者に大きな経済的負担をもたらす可能性があります。治療費の高騰は、市場の成長に影響を与え、血液がん治療薬への患者のアクセスを妨げる可能性があります。

血液がん治療薬は、疲労、吐き気、嘔吐、脱毛、免疫抑制、臓器毒性など、さまざまな副作用を引き起こす可能性があります。これらの副作用は、患者のQOLや治療のアドヒアランスに大きな影響を与える可能性があります。副作用を開拓し、支持療法を開発することは、患者さんの転帰を改善し、血液がん治療薬を市場に受け入れる上で重要な考慮事項です。

COVID-19の影響分析

COVID-19のパンデミックは、血液がん治療薬市場を含むヘルスケア業界に多大な影響を与えました。血液がん患者は、免疫力が低下し、COVID-19による重篤な転帰のリスクが高いため、脆弱であると考えられています。その結果、患者の管理戦略は、ウイルスへの曝露を最小限に抑えるように変更されています。

血液がん治療薬に関連するいくつかの調査活動は、一時的に優先順位が下げられたり、COVID-19関連のプロジェクトに方向転換されたりしている可能性があります。このような研究焦点の転換は、血液がん治療薬市場における医薬品開発および技術革新のペースに影響を与える可能性があります。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は血液がん治療薬市場に大きな影響を及ぼしています。この紛争により、研究機関や製薬会社における研究開発の共同作業が中断される可能性があります。創薬、臨床試験、科学的交流における共同作業が阻害され、新しい血液がん治療薬のイノベーションと開発のペースに影響を与える可能性があります。

ロシアとウクライナの紛争は、血液がん治療薬市場における国際的な協力関係や投資に影響を与える可能性があります。企業や投資家は、地政学的リスクや不確実性により、これらの市場に慎重に接近し、投資や共同研究の減速につながる可能性があります。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • がんの種類別スニペット
  • 治療法別スニペット
  • 投与経路別スニペット
  • エンドユーザー別スニペット
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 血液がんの有病率の増加
      • 標的治療薬と免疫治療薬の開発
    • 抑制要因
      • 高額な治療費
      • 治療に伴う副作用
    • 機会
      • がん研究の進展
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 法規制の分析

第6章 COVID-19の分析

第7章 がん種別

  • 白血病
  • 骨髄腫
  • 非ホジキンリンパ腫
  • ホジキンリンパ腫

第8章 治療法別

  • 化学療法
  • 放射線療法
  • 免疫療法
  • 標的治療
  • その他

第9章 投与経路別

  • 経口
  • 非経口
  • その他

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第13章 企業プロファイル

  • Amgen Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • AstraZeneca Plc
  • Takeda Pharmaceutical Company Ltd
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Bristol-Myers Squibb Company
  • Gilead Sciences Inc.
  • Daiichi Sankyo Company Ltd
  • UCB SA

第14章 付録

目次
Product Code: PH3416

Market Overview

The Global Blood Cancer Drugs Market size reached US$ 63 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 113.5 billion by 2030. The Global Blood Cancer Drugs Market is expected to exhibit a CAGR of 7.8% during the forecast period 2023-2030. The key market trend is the rapid advancements of immunotherapies.

For instance, in April 2023, Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select, a first-of-its-kind molecular profiling test for patients with advanced cancer.

The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit. Blood cancer drugs encompass diverse therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies, and supportive care medications, designed to specifically target and inhibit the growth of cancerous cells in the blood and bone marrow.

These drugs aim to disrupt abnormal cellular processes, suppress cancer cell proliferation, induce apoptosis, and restore normal blood cell production and function.

The blood cancer drugs market is driven by factors such as the increasing prevalence of blood cancers, advancements in cancer research, development of targeted therapies, immunotherapies, and personalized medicine.

For instance, in May 2023, Amneal Pharmaceuticals, Inc. announced the commercial launch of FYLNETRA, a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy.

Market Dynamics

Increasing prevalence of blood cancers

The increasing prevalence of blood cancers is the major factor driving the market share during the forecast period. Blood cancers, particularly certain types such as leukemia, lymphoma, and multiple myeloma, are more commonly diagnosed in older individuals. As the global population continues to age, the overall incidence of blood cancers increases.

Exposure to certain environmental factors and unhealthy lifestyle choices can increase the risk of developing blood cancers. Environmental factors include exposure to radiation, certain chemicals, pesticides, and industrial pollutants. Unhealthy behaviors like smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to the development of blood cancers.

High cost and side effects of treatment

Blood cancer drugs often come with a high price tag due to the extensive research and development efforts involved and the complexity of manufacturing and testing processes. The cost of these drugs can pose a significant financial burden on patients, healthcare systems, and payers. The high cost of treatment can impact market growth and hinder patient access to blood cancer drugs.

Blood cancer drugs can cause various adverse effects, including fatigue, nausea, vomiting, hair loss, immunosuppression, and organ toxicity. These side effects can significantly impact patients' quality of life and treatment adherence. Managing side effects and developing supportive care measures are important considerations in improving patient outcomes and market acceptance of blood cancer drugs.

COVID-19 Impact Analysis

The COVID-19 pandemic has profoundly impacted the healthcare industry, including the blood cancer drugs market. Blood cancer patients are considered vulnerable due to their compromised immune systems and higher risk of severe COVID-19 outcomes. As a result, patient management strategies have been modified to minimize exposure to the virus.

Some research activities related to blood cancer drugs may have been temporarily deprioritized or redirected towards COVID-19-related projects. This shift in research focus may impact the pace of drug development and innovation in the blood cancer drugs market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has significantly impacted the blood cancer drugs market. The conflict may disrupt research and development collaboration in institutions and pharmaceutical companies. Collaborative efforts in drug discovery, clinical trials, and scientific exchange may be hampered, impacting the pace of innovation and development of new blood cancer drugs.

The conflict between Russia and Ukraine may impact international collaborations and investments in the blood cancer drugs market. Companies and investors may approach these markets with caution due to geopolitical risks and uncertainties, potentially leading to a slowdown in investments and collaborations.

Segment Analysis

The Global Blood Cancer Drugs Market is segmented based on cancer type, therapy type, route of administration, End User, and region.

Based on cancer type, the leukemia segment is expected to dominate the market share

The leukemia market will hold 35.8% of the global blood cancer drugs market share in 2022. Leukemia has been the subject of extensive research and development efforts in the field of blood cancer drugs. Significant advancements have been made in understanding the molecular basis of different leukemia subtypes, leading to the development of targeted therapies and immunotherapies.

For instance, in May 2023, Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA, a leading provider of commercialization services to the life science industry, announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older.

Geographical Analysis

North America holds the largest market share due to the presence of key players and advanced healthcare infrastructure

North America holds the 41.3% market share for the blood cancer drugs market in 2022 due to the presence of key players and advanced healthcare infrastructure in the region. North America boasts advanced healthcare infrastructure, including well-established hospitals, research institutions, and oncology centers.

The region has a robust healthcare system that facilitates access to diagnosis, treatment, and follow-up care for blood cancer patients. The availability of state-of-the-art medical facilities, advanced diagnostic technologies, and specialized healthcare professionals supports the demand for blood cancer drugs and drives market growth.

Competitive Landscape

The major global players in the market include: Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.

Why Purchase the Report?

  • To visualize the Global Blood Cancer Drugs Market segmentation based on cancer type, therapy type, route of administration, End User, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of blood cancer drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Blood Cancer Drugs Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Therapy Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of blood cancers
      • 4.1.1.2. Development of targeted therapies and immunotherapies
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of treatment
      • 4.1.2.2. Side effects associated with treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Advancements in cancer research
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Leukemia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Myeloma
  • 7.4. Non-Hodgkin Lymphoma
  • 7.5. Hodgkin Lymphoma

8. By Therapy Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 8.1.2. Market Attractiveness Index, By Therapy Type
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Radiation Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Amgen Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. AstraZeneca Plc
  • 13.3. Takeda Pharmaceutical Company Ltd
  • 13.4. Bayer AG
  • 13.5. Celgene Corporation
  • 13.6. Eli Lilly
  • 13.7. Bristol-Myers Squibb Company
  • 13.8. Gilead Sciences Inc.
  • 13.9. Daiichi Sankyo Company Ltd
  • 13.10. UCB SA

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us